目的评价莫沙必利对功能性便秘的临床治疗效果。方法采用随机双盲安慰剂对照方法,观察58例功能性便秘患者治疗前后排便次数、大便性状、排便困难症状评分、胃肠传输时间。结果①人均周排便次数莫沙必利组由治疗前基线期(2.4±0.4)...目的评价莫沙必利对功能性便秘的临床治疗效果。方法采用随机双盲安慰剂对照方法,观察58例功能性便秘患者治疗前后排便次数、大便性状、排便困难症状评分、胃肠传输时间。结果①人均周排便次数莫沙必利组由治疗前基线期(2.4±0.4)次增加至治疗后第2周的(5.0±0.5)次(P<0.05);安慰剂组基线期为(2.3±0.1)次,治疗后第2周为(3.25±0.5)次(P>0.05);治疗后第2周莫沙必利组较安慰剂组增加明显(P<0.05)。②莫沙必利组大便性状由治疗前基线期人均(2.5±0.5)分改善为治疗后第2周的(5.1±0.1)分(P<0.05),而安慰剂组分别为(2.0±0.3)分和(2.5±0.5)分。③莫沙必利组排便困难症状人均评分由治疗前基线期11.25±0.75下降为治疗后5.5±0.22(P<0.05),但安慰剂组分别为10.2±0.55和3.35±0.51(P<0.05),两组间差异无统计学意义(P>0.05)。④莫沙必利组治疗前后平均钡条残留率分别为68%±7%和41%±3%(P<0.05),安慰剂组也由治疗前的70%±5%降为治疗后的45%±5%(P<0.05),但莫沙必利组和安慰剂组治疗前后胃肠传输时间变化值差异有统计学意义(38.8±0.2 vs 33.3±0.14,P<=0.05)。结论莫沙必利能增加功能性便秘患者的排便次数、改善大便性状、加快胃肠传输时间,较安慰剂组明显,但对排便困难症状改善两组间差异无统计学意义(P>0.05)。展开更多
AIM: To determine the efficacy of probiotic supplementation on intestinal transit time (ITT) and to identify factors that influence these outcomes. METHODS: A systematic review of randomized controlled trials (RCTs) o...AIM: To determine the efficacy of probiotic supplementation on intestinal transit time (ITT) and to identify factors that influence these outcomes. METHODS: A systematic review of randomized controlled trials (RCTs) of probiotic supplementation that measured ITT in adults was conducted by searching MEDLINE and EMBASE using relevant combinations. Main search limits included RCTs of probiotic supplementation in healthy or constipated adults that measured ITT. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference (SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses were conducted to examine the impact of moderator variables on ITT SMD. RESULTS: A total of 11 clinical trials with 13 treatment effects representing 464 subjects were included in this analysis. Probiotic supplementation was associated with decreased ITT in relation to controls, with an SMD of 0.40 (95%CI: 0.20-0.59, P < 0.001). Constipation (r 2 = 39%, P = 0.01), higher mean age (r 2 = 27%, P = 0.03), and higher percentage of female subjects (r 2 = 23%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation and in older vs younger subjects [both SMD: 0.59 (95%CI: 0.39-0.79) vs 0.17 (95%CI: -0.08-0.42), P = 0.01]. Medium to large treatment effects were identified with Bifidobacterium Lactis (B. lactis ) HN019 (SMD: 0.72, 95%CI: 0.27-1.18, P < 0.01) and B. lactis DN-173 010 (SMD: 0.54, 95%CI: 0.15-0.94, P < 0.01) while other single strains and combination products yielded small treatment effects. CONCLUSION: Overall, short-term probiotic supplementation decreases ITT with consistently greater treatment effects identified in constipated or older adults and with certain probiotic strains.展开更多
目的观察加味三香汤对功能性腹胀(FB)患者中医症状改善及胃肠传输功能的影响。方法将60例FB患者随机分为中药组40例和对照组20例。中药组予加味三香汤,对照组予安慰剂颗粒,每次1袋,每日2次,冲服。2组均治疗21 d。观察2组治疗前后中医症...目的观察加味三香汤对功能性腹胀(FB)患者中医症状改善及胃肠传输功能的影响。方法将60例FB患者随机分为中药组40例和对照组20例。中药组予加味三香汤,对照组予安慰剂颗粒,每次1袋,每日2次,冲服。2组均治疗21 d。观察2组治疗前后中医症状积分、48 h胃肠通过率(48 h GITT),并记录不良反应情况。结果 2组治疗后中医症状积分与治疗前比较,差异有统计学意义(P<0.05)。治疗后,中药组腹胀、嗳气、纳差积分及中医症状总分均低于对照组,差异有统计学意义(P=0.000、0.000、0.010、0.003)。中药组总有效率为82%(33/40),对照组为30%(6/20),中药组疗效优于对照组(P<0.05)。共30例完成胃肠传输试验,其中48 h GITT延缓者占54%(16/30)。中药组48 h GITT较对照组改善更明显,2组比较差异有统计学意义(P=0.002)。2组均未见明显不良反应。结论 FB患者多存在肠动力异常情况,加味三香汤能够改善FB中医症状,促进肠动力,改善肠道传输功能。展开更多
Objective To explore clinical efficacy and safety of acupuncture in treatment of functional constipation.Methods One hundred and twenty cases were randomly divided into an observation group and a control group,60 case...Objective To explore clinical efficacy and safety of acupuncture in treatment of functional constipation.Methods One hundred and twenty cases were randomly divided into an observation group and a control group,60 cases in each group.The patients in the observation group were treated with acupuncture at Tiānshū（天枢 ST 25）,Shàngjùxū（上巨虚 ST 37）,Zúsānlǐ（足三里 ST 36）,Dàchángshū（大肠俞 BL 25）,etc.,and the control group was treated with oral administration of Macrogol 4000 and Mosapride.Defecation frequency,stool property,constipation symptom score,accompanying symptom score,gastrointestinal transit time and adverse reaction were observed before treatment,at the end of treatment and 4 weeks after treatment in the two groups.Results Compared with those before treatment,defecation frequency was increased significantly at the end of treatment in the two groups,while stool property,constipation symptom score,accompanying syndrome score and gastrointestinal transit time all were decreased significantly（all P0.01）,with no significant difference in these indexes between the two groups at the end of treatment （all P0.05）.Compared with the end of treatment,the above-mentioned indexes did not significantly recur in the observation group 4 weeks after the treatment （all P0.05）,but the therapeutic effects were unstable with decreased to some extent in the control group （all P0.05）.No serious adverse reaction was found in the two groups.Conclusion In the patients with functional constipation,acupuncture can significantly increase defecation frequency,change stool property,alleviate constipation and accompanying symptoms,and shorten gastrointestinal transit time with better safety and tolerance,and the therapeutic effect is more stable than that of Macrogol 4000 and Mosapride.展开更多
AIM: To determine the efficacy of probiotic supplementation on intestinal transit time(ITT) in adults and to identify factors that influence these outcomes. METHODS: We conducted a systematic review of randomized cont...AIM: To determine the efficacy of probiotic supplementation on intestinal transit time(ITT) in adults and to identify factors that influence these outcomes. METHODS: We conducted a systematic review of randomized controlled trials of probiotic supplementation that measured ITT in adults. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference(SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses examined the impact of moderator variables on SMD of ITT.RESULTS: A total of 15 clinical trials with 17 treatment effects representing 675 subjects were included in this analysis. Probiotic supplementation was moderately efficacious in decreasing ITT compared to control, with an SMD of 0.38(95%CI: 0.23-0.53, P < 0.001). Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation(SMD: 0.57 vs 0.22, P < 0.01) and in studies with high vs low study quality(SMD: 0.45 vs 0.00, P = 0.01). Constipation(R^2 = 38%, P < 0.01), higher study quality(R^2 = 31%, P = 0.01), older age(R^2 = 27%, P = 0.02), higher percentage of female subjects(R^2 = 26%, P = 0.02), and fewer probiotic strains(R^2 = 20%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Medium to large treatment effects were identified with B. lactis HN019(SMD: 0.67, P < 0.001) and B. lactis DN-173 010(SMD: 0.54, P < 0.01) while other probiotic strains yielded negligible reductions in ITT relative to control.CONCLUSION: Probiotic supplementation is moderately efficacious for reducing ITT in adults. Probiotics were most efficacious in constipated subjects, when evaluated in high-quality studies, and with certain probiotic strains.展开更多
文摘目的评价莫沙必利对功能性便秘的临床治疗效果。方法采用随机双盲安慰剂对照方法,观察58例功能性便秘患者治疗前后排便次数、大便性状、排便困难症状评分、胃肠传输时间。结果①人均周排便次数莫沙必利组由治疗前基线期(2.4±0.4)次增加至治疗后第2周的(5.0±0.5)次(P<0.05);安慰剂组基线期为(2.3±0.1)次,治疗后第2周为(3.25±0.5)次(P>0.05);治疗后第2周莫沙必利组较安慰剂组增加明显(P<0.05)。②莫沙必利组大便性状由治疗前基线期人均(2.5±0.5)分改善为治疗后第2周的(5.1±0.1)分(P<0.05),而安慰剂组分别为(2.0±0.3)分和(2.5±0.5)分。③莫沙必利组排便困难症状人均评分由治疗前基线期11.25±0.75下降为治疗后5.5±0.22(P<0.05),但安慰剂组分别为10.2±0.55和3.35±0.51(P<0.05),两组间差异无统计学意义(P>0.05)。④莫沙必利组治疗前后平均钡条残留率分别为68%±7%和41%±3%(P<0.05),安慰剂组也由治疗前的70%±5%降为治疗后的45%±5%(P<0.05),但莫沙必利组和安慰剂组治疗前后胃肠传输时间变化值差异有统计学意义(38.8±0.2 vs 33.3±0.14,P<=0.05)。结论莫沙必利能增加功能性便秘患者的排便次数、改善大便性状、加快胃肠传输时间,较安慰剂组明显,但对排便困难症状改善两组间差异无统计学意义(P>0.05)。
文摘AIM: To determine the efficacy of probiotic supplementation on intestinal transit time (ITT) and to identify factors that influence these outcomes. METHODS: A systematic review of randomized controlled trials (RCTs) of probiotic supplementation that measured ITT in adults was conducted by searching MEDLINE and EMBASE using relevant combinations. Main search limits included RCTs of probiotic supplementation in healthy or constipated adults that measured ITT. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference (SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses were conducted to examine the impact of moderator variables on ITT SMD. RESULTS: A total of 11 clinical trials with 13 treatment effects representing 464 subjects were included in this analysis. Probiotic supplementation was associated with decreased ITT in relation to controls, with an SMD of 0.40 (95%CI: 0.20-0.59, P < 0.001). Constipation (r 2 = 39%, P = 0.01), higher mean age (r 2 = 27%, P = 0.03), and higher percentage of female subjects (r 2 = 23%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation and in older vs younger subjects [both SMD: 0.59 (95%CI: 0.39-0.79) vs 0.17 (95%CI: -0.08-0.42), P = 0.01]. Medium to large treatment effects were identified with Bifidobacterium Lactis (B. lactis ) HN019 (SMD: 0.72, 95%CI: 0.27-1.18, P < 0.01) and B. lactis DN-173 010 (SMD: 0.54, 95%CI: 0.15-0.94, P < 0.01) while other single strains and combination products yielded small treatment effects. CONCLUSION: Overall, short-term probiotic supplementation decreases ITT with consistently greater treatment effects identified in constipated or older adults and with certain probiotic strains.
文摘目的观察加味三香汤对功能性腹胀(FB)患者中医症状改善及胃肠传输功能的影响。方法将60例FB患者随机分为中药组40例和对照组20例。中药组予加味三香汤,对照组予安慰剂颗粒,每次1袋,每日2次,冲服。2组均治疗21 d。观察2组治疗前后中医症状积分、48 h胃肠通过率(48 h GITT),并记录不良反应情况。结果 2组治疗后中医症状积分与治疗前比较,差异有统计学意义(P<0.05)。治疗后,中药组腹胀、嗳气、纳差积分及中医症状总分均低于对照组,差异有统计学意义(P=0.000、0.000、0.010、0.003)。中药组总有效率为82%(33/40),对照组为30%(6/20),中药组疗效优于对照组(P<0.05)。共30例完成胃肠传输试验,其中48 h GITT延缓者占54%(16/30)。中药组48 h GITT较对照组改善更明显,2组比较差异有统计学意义(P=0.002)。2组均未见明显不良反应。结论 FB患者多存在肠动力异常情况,加味三香汤能够改善FB中医症状,促进肠动力,改善肠道传输功能。
文摘Objective To explore clinical efficacy and safety of acupuncture in treatment of functional constipation.Methods One hundred and twenty cases were randomly divided into an observation group and a control group,60 cases in each group.The patients in the observation group were treated with acupuncture at Tiānshū（天枢 ST 25）,Shàngjùxū（上巨虚 ST 37）,Zúsānlǐ（足三里 ST 36）,Dàchángshū（大肠俞 BL 25）,etc.,and the control group was treated with oral administration of Macrogol 4000 and Mosapride.Defecation frequency,stool property,constipation symptom score,accompanying symptom score,gastrointestinal transit time and adverse reaction were observed before treatment,at the end of treatment and 4 weeks after treatment in the two groups.Results Compared with those before treatment,defecation frequency was increased significantly at the end of treatment in the two groups,while stool property,constipation symptom score,accompanying syndrome score and gastrointestinal transit time all were decreased significantly（all P0.01）,with no significant difference in these indexes between the two groups at the end of treatment （all P0.05）.Compared with the end of treatment,the above-mentioned indexes did not significantly recur in the observation group 4 weeks after the treatment （all P0.05）,but the therapeutic effects were unstable with decreased to some extent in the control group （all P0.05）.No serious adverse reaction was found in the two groups.Conclusion In the patients with functional constipation,acupuncture can significantly increase defecation frequency,change stool property,alleviate constipation and accompanying symptoms,and shorten gastrointestinal transit time with better safety and tolerance,and the therapeutic effect is more stable than that of Macrogol 4000 and Mosapride.
文摘AIM: To determine the efficacy of probiotic supplementation on intestinal transit time(ITT) in adults and to identify factors that influence these outcomes. METHODS: We conducted a systematic review of randomized controlled trials of probiotic supplementation that measured ITT in adults. Study quality was assessed using the Jadad scale. A random effects meta-analysis was performed with standardized mean difference(SMD) of ITT between probiotic and control groups as the primary outcome. Meta-regression and subgroup analyses examined the impact of moderator variables on SMD of ITT.RESULTS: A total of 15 clinical trials with 17 treatment effects representing 675 subjects were included in this analysis. Probiotic supplementation was moderately efficacious in decreasing ITT compared to control, with an SMD of 0.38(95%CI: 0.23-0.53, P < 0.001). Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation(SMD: 0.57 vs 0.22, P < 0.01) and in studies with high vs low study quality(SMD: 0.45 vs 0.00, P = 0.01). Constipation(R^2 = 38%, P < 0.01), higher study quality(R^2 = 31%, P = 0.01), older age(R^2 = 27%, P = 0.02), higher percentage of female subjects(R^2 = 26%, P = 0.02), and fewer probiotic strains(R^2 = 20%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression. Medium to large treatment effects were identified with B. lactis HN019(SMD: 0.67, P < 0.001) and B. lactis DN-173 010(SMD: 0.54, P < 0.01) while other probiotic strains yielded negligible reductions in ITT relative to control.CONCLUSION: Probiotic supplementation is moderately efficacious for reducing ITT in adults. Probiotics were most efficacious in constipated subjects, when evaluated in high-quality studies, and with certain probiotic strains.
